华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03320 华润医药

交易中 07-24 09:36:09

4.840

-0.020

-0.41%

最高4.880	最低4.830	成交量24.65万
今开4.840	昨收4.860	日振幅1.03%
总市值304.10亿	流通市值304.07亿	总股本62.83亿
成交额119.53万	换手率0.00%	流通股本62.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03320","market":"HK","secType":"STK","nameCN":"华润医药","latestPrice":4.84,"timestamp":1784856966152,"preClose":4.86,"halted":0,"volume":246500,"delay":0,"changeRate":-0.0041152263374486546,"floatShares":6282510461,"shares":6283000000,"eps":0.643391,"marketStatus":"交易中","change":-0.02,"latestTime":"07-24 09:36:09","open":4.84,"high":4.88,"low":4.83,"amount":1195266,"amplitude":0.010288,"askPrice":4.84,"askSize":66000,"bidPrice":4.82,"bidSize":54000,"shortable":3,"etf":0,"ttmEps":0.715972,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784865600000},"marketStatusCode":2,"adr":0,"listingDate":1477584000000,"exchange":"SEHK","adjPreClose":4.86,"dividendRate":0.046377,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":1.349933,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03320","defaultTab":"news","newsList":[{"id":"2653759599","title":"华润医药(03320)完成发行第一期2026年中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759599","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653759599?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:03","pubTimestamp":1784714626,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，于2026年7月21日，本公司的全资附属公司华润医药控股有限公司(华润医药控股)已于中国完成发行第一期2026年中期票据(第一期2026年中期票据)。本金额人民币10亿元的第一期2026年中期票据已发行，期限三年，票面年利率为1.53%。发行第一期2026年中期票据所得募集资金将用于补充营运资金、偿还有息债务及其他合符适用法例法规的用途。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1570","BK1191","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653759518","title":"华润医药(03320.HK)完成发行第一期2026年中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759518","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653759518?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:03","pubTimestamp":1784714626,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03320","BK1570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651584492","title":"【券商聚焦】光大证券：议优先布局经营稳健、业绩扎实或者股息类中药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651584492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651584492?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:54","pubTimestamp":1784163265,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券研究指，近期，中药板块持续上涨，主要受到市场避险、政策利好、业绩催化和估值底部等多重因素共同推动，中期配置价值显著，后市偏乐观。建议优先布局经营稳健、业绩扎实或者高股息类中药标的。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BK1515","BK0276","00570","601788","03613","BK0012","BK1570","BK1606","VIG","BK0028","BK1191","BK1521","00874","06178","BK1219","BK0188","03320","BK4588","BK1147","BK1197","BK1564","BK0183","BK4585","02273","02877","01643","02161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651046137","title":"华润医药(03320.HK)附属华润双鹤可能收购利尔化学部分股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2651046137","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651046137?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:18","pubTimestamp":1784125098,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1570","03320","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169720927","title":"华润医药（03320）获确认为利尔化学23.50%股权首位意向受让方","url":"https://stock-news.laohu8.com/highlight/detail?id=1169720927","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169720927?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:15","pubTimestamp":1784124944,"startTime":"0","endTime":"0","summary":"华润医药集团有限公司7月15日公告，其间接非全资附属公司华润双鹤药业股份有限公司已参与由四川久远投资控股集团有限公司及四川化材科技有限公司通过公开征集转让方式出售的利尔化学股份有限公司股份项目，并被确认为排名第一的意向受让方。\\n\\n 根据公告，待转让股份为188,102,749股，约占利尔化学已发行股本的23.50%。目前，华润双鹤并未持有利尔化学任何股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167711416","title":"华润医药旗下双鹤药业于2026年7月15日竞购利尔化学股份中拔得头筹","url":"https://stock-news.laohu8.com/highlight/detail?id=1167711416","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167711416?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:15","pubTimestamp":1784124918,"startTime":"0","endTime":"0","summary":"在2026年7月15日进行的一场股权竞购中，华润医药集团旗下的双鹤药业成功脱颖而出，在针对利尔化学股份的竞标中位列第一。这一进展标志着华润医药在拓展其产业布局方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320","BK1570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651461696","title":"华润医药：拟收购利尔化学约23.50%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2651461696","media":"南方财经网","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651461696?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:13","pubTimestamp":1784124780,"startTime":"0","endTime":"0","summary":"南财智讯7月15日电，华润医药（03320.HK）发布内幕消息公告，公司间接非全资附属公司华润双鹤药业股份有限公司已参与由四川久远投资控股集团有限公司及四川化材科技有限公司发起的公开征集转让方式，拟受让其合计持有的利尔化学股份有限公司（股票代码：002258）18810.27万股股份，占利尔化学股权约23.50%。截至公告日，华润双鹤未持有利尔化学任何股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807789855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002258","BK0229","03320","BK0122","BK0028","BK0186","BK1191","BK1570","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132969918","title":"华润医药披露天士力医药2026年上半年业绩：归母净利8.93亿元，同比增15.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132969918","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132969918?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:40","pubTimestamp":1784029250,"startTime":"0","endTime":"0","summary":"2026年7月14日，华润医药公告披露，其通过非全资子公司华润三九医药股份有限公司持股约28%的天士力医药集团股份有限公司公布了截至2026年6月30日止六个月的未经审计初步财务数据。天士力医药在报告期内实现营业总收入42.01亿元，同比下降2.03%；实现营业利润10.48亿元，同比增长14.87%；利润总额10.46亿元，同比增长15.67%。华润医药提醒，以上数据基于中国公认会计准则编制且未经审计，相关最终财务信息以天士力医药即将发布的2026年中期报告为准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651108544","title":"华润医药(03320)：天士力医药上半年归母净利润为8.93亿元，同比增长15.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651108544","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651108544?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:40","pubTimestamp":1784029209,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)公布，于2026年上半年，天士力医药实现营业总收入人民币42.01亿元(同比下跌2.03%，主要由于中药注射剂行业整体下滑，以及感冒发烧药物的销售收入较去年同期减少)，上市公司股东应占净利润人民币8.93亿元，同比增长15.23%;上市公司股东应占净利润(扣除非经常性损益)人民币8.71亿元，同比增长36.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320","09939","600535","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651108348","title":"华润医药(03320.HK)：华润三九上半年实现归母净利润16.72亿元 同比下降7.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651108348","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651108348?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:37","pubTimestamp":1784029063,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1570","03320","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178819480","title":"华润医药(03320)：控股子公司华润三九2026年上半年收入150.13亿元，同比增长1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178819480","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178819480?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:35","pubTimestamp":1784028949,"startTime":"0","endTime":"0","summary":"2026年7月14日，华润医药公告称，其控股63.22%的子公司华润三九医药股份有限公司披露了截至2026年6月30日止六个月的未经审计初步财务数据。华润三九在报告期内实现营业总收入150.13亿元，同比增加1.37%；实现营业利润24.98亿元，同比下降4.67%；利润总额25.34亿元，同比下降3.48%。截至2026年6月30日，华润三九总资产为558.57亿元，较期初减少5.01%；上市公司股东应占权益为228.74亿元，较期初增长3.17%；每股净资产13.74元，较期初增长3.15%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651174363","title":"华润医药(03320.HK)：昆药集团预计中期归母净亏损为3.3亿元至4亿元  同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2651174363","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651174363?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:06","pubTimestamp":1784023560,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03320","BK1191","BK1570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152540381","title":"华润医药（03320）披露昆药集团2026年上半年业绩预告：预计净亏损最高4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152540381","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152540381?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:01","pubTimestamp":1784023309,"startTime":"0","endTime":"0","summary":"2026年7月14日，华润医药集团有限公司公告称，其附属公司华润三九医药股份有限公司持股约29.08%的昆药集团股份有限公司发布了截至2026年6月30日止六个月的未经审计初步财务资料。华润医药提醒股东及潜在投资者，在买卖公司证券时务请保持谨慎，避免仅依赖上述未经审计数据作出投资决策。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139633823","title":"华润医药（03320）公布董事会及五大专门委员会最新成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1139633823","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139633823?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:36","pubTimestamp":1783931788,"startTime":"0","endTime":"0","summary":"2026年7月13日，华润医药发布公告，披露董事会成员及其在执行委员会、审计委员会、薪酬与考核委员会、提名委员会及企业管治委员会五大专门委员会中的最新职务安排。公告显示，公司通过完善董事会及各专门委员会架构，明确了董事在不同专业领域的职责与分工。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160240980","title":"华润医药（03320）董事会人事调整：郭川辞任、张静获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1160240980","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160240980?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:36","pubTimestamp":1783931770,"startTime":"0","endTime":"0","summary":"华润医药7月13日晚间公告称，自2026年7月13日起，公司董事会将进行以下调整：郭川先生因其他工作安排辞任非执行董事；张静女士被委任为非执行董事。董事会对郭先生任职期间的贡献表示感谢，并对张女士的加入表示欢迎。在上述变动生效后，华润医药董事会将由12名董事组成：主席兼执行董事白晓松，执行董事程杰、刘长安；非执行董事郭巍、孙永强、王宇航、张静、焦瑞芳；独立非执行董事招敏慧、傅廷美、张克坚及史录文。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194174","title":"华润医药(03320)：张静获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194174","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651194174?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:33","pubTimestamp":1783931612,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，自2026年7月13日起，郭川先生辞任非执行董事;及张静女士获委任为非执行董事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320","BK1570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135651289","title":"华润医药6月股份变动月报：股本规模保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1135651289","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135651289?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:37","pubTimestamp":1782985048,"startTime":"0","endTime":"0","summary":"华润医药于2026年7月2日披露了截至2026年6月30日的证券变动月报，显示公司本月未发生新的股份发行、购回及库存股变动，股本规模保持不变。\n截至2026年6月底，华润医药已发行普通股合计6,282,510,461股，与上月末持平。报告同时显示，公司确认符合香港联交所规定的公众持股量要求。公司在本月并无因股份期权行使而发行新股或产生新的库藏股，期权持有人本月底可行使的股份期权数量为628,450,646股。\n公告由公司秘书温詠宜代表华润医药签署。公司表示将继续遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354124","title":"华润医药(03320.HK)附属华润医药商业完成发行20亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646354124?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:38","pubTimestamp":1782473932,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1570","BK1191","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128048162","title":"华润医药5月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128048162","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128048162?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:01","pubTimestamp":1780304513,"startTime":"0","endTime":"0","summary":"华润医药（股票代码：03320）于2026年6月1日发布截至2026年5月31日的股份变动月报表。报告显示，公司于5月底的已发行股份总数为6,282,510,461股，与上月底持平，未发生新的股票发行、购回或注销及库藏股变动。\n根据月报，现行股份期权计划并未在报告期内产生行使或失效情况。截至5月底，该期权计划下潜在可发行或转让的股份数为628,450,646股。公司同时表示已满足相关监管规定的公众持股量要求。\n本次公告由公司秘书温詠宜签署。公司确认将继续遵守香港联交所《上市规则》及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639627642","title":"华润医药(03320)附属获准发行50亿元的中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639627642","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639627642?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:22","pubTimestamp":1780057377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)公布，公司的全资附属公司华润医药控股有限公司收到中国银行间市场交易商协会发出关于华润医药控股拟于中华人民共和国发行中期票据的接受注册通知书( 中市协注[ 2026 ]MTN455号 )。通知书自通知书发出日期起两年内有效，华润医药控股可在该期间内分期发行总额为人民币50亿元的中期票据。倘进行中期票据的拟议发行，则预计所得募集资金将主要用于补充营运资金、偿还有息债务及其他合符适用法例法规的用途。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320","BK1570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crpharm.com","stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":0.0824},{"period":"3month","weight":-0.1335},{"period":"6month","weight":0.0887},{"period":"1year","weight":-0.078},{"period":"ytd","weight":0.1255}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.0803},{"period":"3month","weight":-0.0295},{"period":"6month","weight":-0.0575},{"period":"1year","weight":-0.0128},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华润医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司通过四个分部运营业务。制药业务分部研发、制造及销售一系列药品及保健品。药品分销业务分部向医院、分销商及零售药店等药品制造商、器械制造商及配药商提供分销、仓储、物流及其他药品供应链增值解决方案及相关服务。药品零售业务分部经营零售药店。其他业务营运分部从事持有物业及其他业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.012765},{"month":2,"riseRate":0.7,"avgChangeRate":0.045371},{"month":3,"riseRate":0.5,"avgChangeRate":0.003211},{"month":4,"riseRate":0.7,"avgChangeRate":0.030284},{"month":5,"riseRate":0.5,"avgChangeRate":0.000669},{"month":6,"riseRate":0.3,"avgChangeRate":-0.002129},{"month":7,"riseRate":0.3,"avgChangeRate":-0.0236},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.002102},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.02076},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.027129},{"month":11,"riseRate":0.4,"avgChangeRate":0.010245},{"month":12,"riseRate":0.5,"avgChangeRate":-0.000965}],"exchange":"SEHK","name":"华润医药","nameEN":"CHINARES PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润医药,03320,华润医药股票,华润医药股票老虎,华润医药股票老虎国际,华润医药行情,华润医药股票行情,华润医药股价,华润医药股市,华润医药股票价格,华润医药股票交易,华润医药股票购买,华润医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}